<HTML>

<BODY>
<P>Do not reply to this email message.</P>

<P> FPR <b>{!PubReviewTeam__c.PubIDLink__c}</b> has been reviewed and is now complete. Reviewer comments should be addressed prior to external submission or presentation and can be accessed using the link below.<br>

<br>Contact the FPR coordinator, {!PubReviewTeam__c.AssignedFPRCFF__c}, If you have questions or need support.<br></P>

<P><b>LEGAL AND COMPLIANCE DISCLAIMER:</b> If an electronic copy of the publication is submitted to external reviewers or meeting/journal, please ensure the following: <br>
•	There are no embedded data (links to data or confidential information). Pay special attention to tables and/or figures generated from underlying Excel spreadsheets that may contain Amgen Confidential Information. <br>
•	Remove proprietary information that may appear in the Speaker Notes of oral presentations. <br>
•	Set the security on all documents. Note that PDFs are editable unless secured. <br>
•	Be aware that Amgen may not wish to disclose AMG numbers for early-phase products.<br> 
•	Remove “Amgen Confidential” from versions of documents to be publicly disseminated. <br><br>

Please note that the FPR process does not fulfill the Amgen requirement for Final Review by All Authors. Refer to the Amgen Publications SOP (014321-7.0) for policy and standard practices across all groups that collaborate with outside authors.
</P>

<br>{!PubReviewTeam__c.PubIDLink__c}<br>

<br><br>Thank you,
<br>FPR System
</P>

<BODY>
<HTML>